Marta Weinstock-Rosin
Directeur/Bestuurslid bij Avraham Pharmaceuticals Ltd.
Actieve functies van Marta Weinstock-Rosin
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
Avraham Pharmaceuticals Ltd.
 Avraham Pharmaceuticals Ltd. BiotechnologyHealth Technology Avraham Pharmaceuticals Ltd. develops pharmaceutical products for prevention and treatment of neurodegenerative disorders. Its lead product candidate, Ladostigil is designed to provide treatment for Mild Cognitive Impairment. The firm’s product candidate is a multifunctional compound that combines neuroprotective mechanisms: reducing oxidative stress and microglial activation, and inhibiting proinflamtory cytokines. The company was founded in 2010 by David Warshawsky and is headquartered in Yavneh, Israel. | Directeur/Bestuurslid | - | - |
| The Hebrew University of Jerusalem | Corporate Officer/Principal | - | - |
Loopbaan van Marta Weinstock-Rosin
Eerdere bekende functies van Marta Weinstock-Rosin
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| The Israel Society for Neuroscience | President | - | 01-01-2005 |
Spero Biopharma Ltd.
 Spero Biopharma Ltd. Pharmaceuticals: MajorHealth Technology Spero Biopharma Ltd. develops ladostigil an treatment for mild cognitive impairment. The company was founded by Marta Weinstock-Rosin and is headquartered in Tel Aviv-Yafo, Israel. | Oprichter | - | - |
Statistieken
Internationaal
| Israël | 5 |
Operationeel
| Director/Board Member | 1 |
| Corporate Officer/Principal | 1 |
| President | 1 |
Sectoraal
| Health Technology | 3 |
| Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Bedrijven in privébezit | 3 |
|---|---|
| The Israel Society for Neuroscience | |
Avraham Pharmaceuticals Ltd.
Avraham Pharmaceuticals Ltd. BiotechnologyHealth Technology Avraham Pharmaceuticals Ltd. develops pharmaceutical products for prevention and treatment of neurodegenerative disorders. Its lead product candidate, Ladostigil is designed to provide treatment for Mild Cognitive Impairment. The firm’s product candidate is a multifunctional compound that combines neuroprotective mechanisms: reducing oxidative stress and microglial activation, and inhibiting proinflamtory cytokines. The company was founded in 2010 by David Warshawsky and is headquartered in Yavneh, Israel. | Health Technology |
Spero Biopharma Ltd.
Spero Biopharma Ltd. Pharmaceuticals: MajorHealth Technology Spero Biopharma Ltd. develops ladostigil an treatment for mild cognitive impairment. The company was founded by Marta Weinstock-Rosin and is headquartered in Tel Aviv-Yafo, Israel. | Health Technology |
